BACKGROUND AND OBJECTIVES: Nearly 30% of renal transplant recipients develops BK viremia, a prerequisite for BK nephropathy. Case reports have evaluated treatment options for BK virus, but no controlled studies have assessed prophylactic therapies. Fluoroquinolone antibiotics were studied for prevention of BK viremia after renal transplantation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This retrospective analysis evaluated adult renal transplant recipients with at least one BK viral load (blood) between 90 and 400 days after transplantation. Six to 12 months of co-trimoxazole was used for Pneumocystis prophylaxis. In sulfa-allergic/-intolerant patients, 6 to 12 months of atovaquone with 1 month of a fluoroquinolone was used. Fluoroquinolones can inhibit BK DNA topoisomerase. The two groups studied were those that received 30 days of levofloxacin or ciprofloxacin after transplantation and those that did not. The primary endpoint was BK viremia rates at 1 year. Of note, of the 160 patients not receiving fluoroquinolone prophylaxis, 40 received a fluoroquinolone for treatment of a bacterial infection within 3 months after transplantation. Subgroup analysis evaluating these 40 patients against the 120 who had no exposure to fluoroquinolones was completed. RESULTS: A 1-month fluoroquinolone course after transplantation was associated with significantly lower rates of BK viremia at 1 year compared with those with no fluoroquinolone. In the subgroup analysis, exposure to fluoroquinolone for treatment of bacterial infections within 3 months after transplantation was associated with significantly lower 1-year rates of BK viremia. CONCLUSIONS: This analysis demonstrates that fluoroquinolones are effective at preventing BK viremia after renal transplantation.
BACKGROUND AND OBJECTIVES: Nearly 30% of renal transplant recipients develops BK viremia, a prerequisite for BK nephropathy. Case reports have evaluated treatment options for BK virus, but no controlled studies have assessed prophylactic therapies. Fluoroquinolone antibiotics were studied for prevention of BK viremia after renal transplantation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This retrospective analysis evaluated adult renal transplant recipients with at least one BK viral load (blood) between 90 and 400 days after transplantation. Six to 12 months of co-trimoxazole was used for Pneumocystis prophylaxis. In sulfa-allergic/-intolerant patients, 6 to 12 months of atovaquone with 1 month of a fluoroquinolone was used. Fluoroquinolones can inhibit BK DNA topoisomerase. The two groups studied were those that received 30 days of levofloxacin or ciprofloxacin after transplantation and those that did not. The primary endpoint was BK viremia rates at 1 year. Of note, of the 160 patients not receiving fluoroquinolone prophylaxis, 40 received a fluoroquinolone for treatment of a bacterial infection within 3 months after transplantation. Subgroup analysis evaluating these 40 patients against the 120 who had no exposure to fluoroquinolones was completed. RESULTS: A 1-month fluoroquinolone course after transplantation was associated with significantly lower rates of BK viremia at 1 year compared with those with no fluoroquinolone. In the subgroup analysis, exposure to fluoroquinolone for treatment of bacterial infections within 3 months after transplantation was associated with significantly lower 1-year rates of BK viremia. CONCLUSIONS: This analysis demonstrates that fluoroquinolones are effective at preventing BK viremia after renal transplantation.
Authors: Anskar Y H Leung; Maggie T L Chan; Kwok-Yung Yuen; Vincent C C Cheng; Kwok-Hung Chan; Chris L P Wong; Raymond Liang; Albert K W Lie; Yok-Lam Kwong Journal: Clin Infect Dis Date: 2005-01-21 Impact factor: 9.079
Authors: Raymund R Razonable; Robert A Brown; Atul Humar; Emma Covington; Emma Alecock; Carlos V Paya Journal: J Infect Dis Date: 2005-09-14 Impact factor: 5.226
Authors: Brahm Vasudev; Sundaram Hariharan; Syed A Hussain; Yong-Ran Zhu; Barbara A Bresnahan; Eric P Cohen Journal: Kidney Int Date: 2005-10 Impact factor: 10.612
Authors: M Portolani; P Pietrosemoli; C Cermelli; A Mannini-Palenzona; M P Grossi; L Paolini; G Barbanti-Brodano Journal: Antiviral Res Date: 1988-04 Impact factor: 5.970
Authors: Daniel C Brennan; Irfan Agha; Daniel L Bohl; Mark A Schnitzler; Karen L Hardinger; Mark Lockwood; Stephanie Torrence; Rebecca Schuessler; Tiffany Roby; Monique Gaudreault-Keener; Gregory A Storch Journal: Am J Transplant Date: 2005-03 Impact factor: 8.086
Authors: Emilio Ramos; Cinthia B Drachenberg; Miguel Portocarrero; Ravinder Wali; David K Klassen; Jeffrey C Fink; Alan Farney; Hans Hirsch; John C Papadimitriou; Charles B Cangro; Matthew R Weir; Stephen T Bartlett Journal: Clin Transpl Date: 2002
Authors: M Radisic; R Lattes; J F Chapman; M del Carmen Rial; O Guardia; F Seu; P Gutierrez; J Goldberg; D H Casadei Journal: Transpl Infect Dis Date: 2003-06 Impact factor: 2.228
Authors: George R Ambalathingal; Ross S Francis; Mark J Smyth; Corey Smith; Rajiv Khanna Journal: Clin Microbiol Rev Date: 2017-04 Impact factor: 26.132